Brokerages expect that Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) will post earnings of ($0.24) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Progenics Pharmaceuticals’ earnings, with estimates ranging from ($0.30) to ($0.18). Progenics Pharmaceuticals reported earnings per share of ($0.19) during the same quarter last year, which suggests a negative year over year growth rate of 26.3%. The company is scheduled to announce its next quarterly earnings report on Wednesday, May 8th.
According to Zacks, analysts expect that Progenics Pharmaceuticals will report full year earnings of ($0.62) per share for the current financial year, with EPS estimates ranging from ($0.67) to ($0.57). For the next year, analysts anticipate that the business will post earnings of ($0.19) per share, with EPS estimates ranging from ($0.41) to $0.03. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Progenics Pharmaceuticals.
Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.14). The company had revenue of $3.24 million during the quarter, compared to analysts’ expectations of $10.99 million. Progenics Pharmaceuticals had a negative return on equity of 59.85% and a negative net margin of 433.09%.
PGNX has been the subject of several recent analyst reports. Zacks Investment Research lowered shares of Progenics Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 19th. BidaskClub raised shares of Progenics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $10.35.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Prudential Financial Inc. grew its holdings in shares of Progenics Pharmaceuticals by 11.3% during the third quarter. Prudential Financial Inc. now owns 136,292 shares of the biotechnology company’s stock worth $855,000 after buying an additional 13,790 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Progenics Pharmaceuticals by 9.8% during the third quarter. Rhumbline Advisers now owns 197,251 shares of the biotechnology company’s stock worth $1,237,000 after buying an additional 17,537 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Progenics Pharmaceuticals by 9.2% during the third quarter. Bank of New York Mellon Corp now owns 1,160,542 shares of the biotechnology company’s stock worth $7,277,000 after buying an additional 97,561 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Progenics Pharmaceuticals by 16.7% during the third quarter. BlackRock Inc. now owns 13,293,243 shares of the biotechnology company’s stock worth $83,349,000 after buying an additional 1,902,006 shares in the last quarter. Finally, Credit Suisse AG grew its holdings in shares of Progenics Pharmaceuticals by 22.2% during the third quarter. Credit Suisse AG now owns 78,520 shares of the biotechnology company’s stock worth $492,000 after buying an additional 14,253 shares in the last quarter. 87.59% of the stock is owned by institutional investors.
Shares of NASDAQ PGNX opened at $5.13 on Friday. The firm has a market capitalization of $444.69 million, a P/E ratio of -8.14 and a beta of 2.45. The company has a quick ratio of 6.15, a current ratio of 6.15 and a debt-to-equity ratio of 0.39. Progenics Pharmaceuticals has a one year low of $3.62 and a one year high of $9.42.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Further Reading: What are the risks of holding treasury bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.